Cancer Anorexia Market to Expand Steadily by 2035

What is Cancer Anorexia and Why Does It Matter?

Cancer anorexia is a serious clinical condition marked by persistent loss of appetite and reduced food intake among cancer patients, particularly those in advanced stages of the disease. Unlike temporary appetite loss, cancer anorexia is a complex, multifactorial disorder influenced by metabolic, inflammatory, and psychological changes associated with cancer and its treatment.

This condition significantly contributes to malnutrition, muscle wasting, and cancer cachexia, ultimately worsening patient outcomes and quality of life. Left unmanaged, cancer anorexia can reduce treatment tolerance, impair immune response, and negatively impact survival rates.

According to BIS Research, the global cancer anorexia market is emerging as a critical segment within oncology supportive care. The market is expected to witness steady growth between 2025 and 2035, driven by increasing cancer incidence, rising recognition of cachexia as a life-threatening condition, and growing demand for effective appetite and weight-management therapies.

Access insights on Cancer Anorexia Market

What’s Driving Growth in the Cancer Anorexia Market?

Key Drivers:?

•    Rising global prevalence of cancer and increasing number of patients experiencing anorexia and cachexia
•    Advancements in appetite stimulants, hormonal therapies, and anti-cachexia drug development
•    Growing awareness among clinicians and patients regarding early diagnosis and intervention
•    Increased research funding and awareness initiatives from organizations such as the National Cancer Institute (NCI) and American Cancer Society (ACS)
•    Expanding focus on combination therapies to address appetite loss, muscle wasting, and fatigue simultaneously

[Request a Sample Report]

What Are the Challenges in the Cancer Anorexia Market?

Key Challenges:
•    Limited efficacy of currently available therapies in managing severe anorexia and cachexia
•    Side effects associated with existing drugs, including fluid retention, weight imbalance, and cognitive complications
•    High costs of innovative biologics and combination therapies, limiting access in low- and middle-income regions
•    Inadequate reimbursement coverage for advanced anorexia treatments in several healthcare systems
•    Absence of universally accepted clinical guidelines, leading to inconsistent treatment approaches and outcomes

 [Download the complete TOC]

What is the Recent Development in Cancer Anorexia Market?

•    Ongoing clinical exploration of ghrelin mimetics as novel appetite-stimulating agents for cancer-related anorexia
•    Increased R&D focus on myostatin inhibitors to reduce muscle wasting associated with cachexia
•    Rising interest in combining appetite stimulants with chemotherapy and immune checkpoint inhibitors
•    Expansion of precision medicine approaches to tailor anorexia treatments based on patient-specific molecular and genetic profiles
•    Growing integration of nutritional support strategies, including enteral and parenteral nutrition, alongside pharmacological therapies

Analyst Perspective: What’s Next for the Cancer Anorexia Market?

According to a Principal Analyst at BIS Research:

“The cancer anorexia market is gradually evolving as awareness of cachexia and appetite loss increases among oncology care providers. Future growth will be shaped by advancements in biologic therapies, ghrelin-based treatments, and precision medicine approaches. Combination therapies that address both metabolic and inflammatory drivers of anorexia will play a key role in improving patient outcomes. As supportive cancer care gains more attention globally, cancer anorexia management is expected to become an integral part of comprehensive oncology treatment strategies.”

FAQs About the Cancer Anorexia Market

What is the expected growth outlook?

The cancer anorexia market is expected to grow steadily through 2035, supported by rising cancer prevalence, increased diagnosis rates, and continued innovation in appetite and cachexia therapies.

Who are the key leaders in this market?

Prominent players operating in the cancer anorexia market include NGM Biopharmaceuticals and Artelo Biosciences, along with several emerging biotech companies focusing on novel biologic and combination therapies.

Which treatment approaches are gaining traction?

Ghrelin mimetics, myostatin inhibitors, and combination therapies integrating appetite stimulants with oncology treatments are gaining significant momentum. Nutritional interventions are also increasingly used as supportive care.

Want to Make Data-Backed Moves in the Oncology Supportive Care Market?

BIS Research offers KOL-based insights, rigorous segmentation, and strategic advisory across software, hardware, and sensing tech domains

Get deeper, tailored insights with a customized report designed around your market, technology focus, and strategic goals.